PharmaEssentia Corp is a Taiwan-based company mainly engaged in the research, development, production and sale of new drugs. The Company is engaged in the research and development of new drugs, which are used for treatment of hematology, such as meloproliferative neoplasms (MPN), neutropenia, anemia; infectious disease, such as hepatitis C and hepatitis B; dermatology, such as psoriasis, and neurology, such as multiple sclerosis, among others. The Companyâs products include KX01, P1101, Polycythemia Vera (PV), PEG-GCSF, PEG-EPO and others. The Company distributes its products within domestic market and to overseas markets.

Employees

131

Sector

Biotechnology & Medical Research

Calendar

06/11/2024 - Q3 2024 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
13/09/24	682.00 NT$	-1.73%	1,417,235
12/09/24	694.00 NT$	+1.31%	1,245,403
11/09/24	685.00 NT$	+0.15%	1,245,975
10/09/24	684.00 NT$	+0.15%	1,949,250
09/09/24	683.00 NT$	-1.01%	2,820,684

End-of-day quote Taiwan S.E., September 12, 2024

More quotes

Income Statement and Estimates

More financial data

Ratings

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

682.00TWD

Average target price

856.00TWD

Spread / Average Target

+25.51%

Consensus

Profit revisions

Estimate revisions

Quarterly earnings, Rate of surprise

Company calendar

End-of-day quote Taiwan S.E. Other stock markets 13/09/2024			5-day change	1st Jan Change
682.00 ^TWD	-1.73%		-1.16%	+97.11%

09-06	PharmaEssentia Corporation Announces Taiwan MOHW Approves IND Application of Phase I Clinical Trial of Sequential Treatment of P1801 Following P1101 in Patients with Advanced Solid Tumors in Principle	CI
09-04	Pharmaessentia Announces Licensing Agreement with Forus Therapeutics to Commercialize Besremi® (Ropeginterferon Alfa-2B-Njft) in Canada	CI

Capitalization	226B 7.07B 538B	P/E ratio 2024 *	67.6x	P/E ratio 2025 *	38.1x
Enterprise value	95B 2.97B 226B	EV / Sales 2024 *	21.4x	EV / Sales 2025 *	13.8x
Free-Float	74.39%	Yield 2024 *	0.15%	Yield 2025 *	0.31%

PharmaEssentia Corporation Announces Taiwan MOHW Approves IND Application of Phase I Clinical Trial of Sequential Treatment of P1801 Following P1101 in Patients with Advanced Solid Tumors in Principle	09-06	CI
Pharmaessentia Announces Licensing Agreement with Forus Therapeutics to Commercialize Besremi® (Ropeginterferon Alfa-2B-Njft) in Canada	09-04	CI
PharmaEssentia Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	08-13	CI
PharmaEssentia Logs NT$1 Billion in H1 Profit; Shares Rise 3%	08-13	MT
Pharmaessentia Corporation Receives Approval of China National Medical Products Administration for Application of Ropeginterferon alfa-2b for PV	07-05	CI
PharmaEssentia Corporation Announces Update on its IND Application of Phase I Clinical Trial of Sequential Treatment of P1801 Following P1101 in Patients with Advanced Solid Tumors	07-02	CI
PharmaEssentia Corporation Announces Changes to Remuneration Committee	06-28	CI
PharmaEssentia Corp. Announces Submission of Marketing Authorization Application of BESREMi (Ropeginterferon alfa-2b) for PV in Argentina	06-16	CI
Pharmaessentia Corporation Announces Term Expiration of Their Fourth Remuneration Committee	05-27	CI
Pharmaessentia Corporation Announces Changes to Members of Third Audit Committee	05-27	CI
Pharmaessentia Corporation Announces Appointments to Board of Directors	05-27	CI
PharmaEssentia Corporation Provides an Update on Submission of P1101 PhaseIII Clinical Study Protocol for Pre-fibrotic/Early PMFor Overt PMF at Low to Intermediate-1 Risk to China NMPA	05-21	CI
PharmaEssentia Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	05-13	CI

PharmaEssentia Announces Licensing Agreement with FORUS Therapeutics to Commercialize BESREMi® (ropeginterferon alfa-2b-njft) in Canada	09-04	BU
PharmaEssentia Appoints Beth A. Krewson as Head of Legal	07-23	AQ
PharmaEssentia - ANALYSES FIND PATIENTS WITH POLYCYTHEMIA VERA TREATED WITH BESREMI HAD INCREASED PROBABILITY OF ACHIEVING COMPLETE HEMATOLOGIC RESPONSE	04-02	AQ
Presentations at MPN Congress and ASH Annual Meeting Reinforce Clinical Role of ropeginterferon alfa-2b-njft	11-02	BU
PharmaEssentia Enters Into Exclusive Global License Agreement With WuXi Biologics for a Myeloid Immune Checkpoint Antibody Candidate	03/10/23	BU

PharmaEssentia Corporation Share Price

Equities

6446

TW0006446008

Biotechnology & Medical Research

Valuation: PharmaEssentia Corporation

Chart: PharmaEssentia Corporation

Latest news: PharmaEssentia Corporation

Press Releases: PharmaEssentia Corporation

News in other languages: PharmaEssentia Corporation

Quotes and Performance

Course Extremes

Managers and Directors: PharmaEssentia Corporation

ETFs: PharmaEssentia Corporation

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Ratings

Analysts' Consensus

Quarterly earnings, Rate of surprise

OPINIONI DEGLI ANALISTI DEL GIORNO: Repsol, LVMH, Enel, Hermès, Intensa, Moncler, BASF, NVIDIA, Nike, TIM, Nordex, Shell...	07-01
AOP Orphan reports full validity of arbitral award against PharmaEssentia	25/03/21

1 day	-1.73%
1 week	-1.16%
Current month	-2.43%
1 month	+3.18%
3 months	+41.49%
6 months	+107.29%
Current year	+97.11%

Director	Title	Age	Since
Kuo Chung Lin CEO	Chief Executive Officer	-	31/12/02
Hsueh Ling Chang DFI	Director of Finance/CFO	-	13/10/15
Albert Qin CTO	Chief Tech/Sci/R&D Officer	-	-

Manager	Title	Age	Since
Ching Liu Chan CHM	Chairman	-	31/08/03
Cheng Ku Huang BRD	Director/Board Member	-	15/01/06
Chao Ho Chen BRD	Director/Board Member	-	29/06/09

Name	Weight	AuM	1st Jan change	Investor Rating
HSBC MSCI TAIWAN UCITS ETF - USD	0.31%	135 M€	+14.83%
LEVERAGE SHARES 3X LONG TAIWAN ETP SECURITIES - USD	0.12%	0 M€	0.00%	-
LEVERAGE SHARES -3X SHORT TAIWAN ETP SECURITIES - USD	0.12%	0 M€	0.00%	-

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi. ($)
PHARMAESSENTIA CORPORATION	-1.73%	-1.16%	+87.62%	+616.39%	7.06B
VERTEX PHARMACEUTICALS INCORPORATED	+1.40%	+3.71%	+38.91%	+157.61%	125B
REGENERON PHARMACEUTICALS, INC.	-0.95%	+1.93%	+38.56%	+78.77%	124B
ARGENX SE	+0.41%	+0.08%	-0.57%	+76.56%	32.35B
BIONTECH SE	+17.52%	+37.20%	+8.43%	-63.15%	29.34B
SUMMIT THERAPEUTICS INC.	+16.49%	+160.23%	+1,571.73%	+398.91%	23.47B
BEIGENE, LTD.	+1.13%	+3.75%	-0.01%	-46.19%	21.1B
GENMAB A/S	+1.18%	-3.23%	-33.58%	-35.25%	16.98B
WUXI APPTEC CO., LTD.	+0.15%	+2.63%	-48.92%	-71.95%	16.01B
VAXCYTE, INC.	+1.64%	+3.96%	+125.24%	+347.53%	14.35B
Average	+3.72%	+20.78%	+178.74%	+145.92%	41.04B
Weighted average by Cap.	+2.51%	+13.56%	+116.57%	+112.44%

	2024 *	2025 *
Net sales	9.65B 302M 23B	14.84B 465M 35.38B
Net income	3.28B 103M 7.82B	5.93B 186M 14.14B
Net Debt	-19.07B -597M -45.46B	-21.38B -670M -50.98B